A ray of hope for ficlatuzumab

AVEO Pharmaceuticals (AVEO) and Biodesix cross license their IP regarding AVEO's hepatocyte growth factor inhibitory antibody and Biodesix's companion diagnostic test for non-small cell lung cancer VeriStrat.

Ficlatuzumab failed to demonstrate efficacy in its Phase 2 clinical trial but an exploratory analysis using VeriStrat identified a sub-group of patients who experienced PFS and OS.

AVEO intends to conduct a new clinical trial (NSCLC POC Trial) on patients selected with the VeriStrat test. Biodesix will fund the trial up to a maximum of $15M. Costs above the maximum will be borne equally.

If the product is approved for commercial sale, the partners will share all profits and losses on a 50/50 basis.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs